

Progressive Supranuclear Palsy - Pipeline Review, H1 2020

<https://marketpublishers.com/r/P8D0E56EDD4EN.html>

Date: June 2020

Pages: 113

Price: US\$ 2,000.00 (Single User License)

ID: P8D0E56EDD4EN

Abstracts

Progressive Supranuclear Palsy - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H1 2020, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape. Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers

therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 8, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous

System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Progressive Supranuclear Palsy - Overview

Progressive Supranuclear Palsy - Therapeutics Development

Progressive Supranuclear Palsy - Therapeutics Assessment

Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development

Progressive Supranuclear Palsy - Drug Profiles

Progressive Supranuclear Palsy - Dormant Projects

Progressive Supranuclear Palsy - Discontinued Products

Progressive Supranuclear Palsy - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Progressive Supranuclear Palsy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Progressive Supranuclear Palsy - Pipeline by AbbVie Inc, H1 2020
Progressive Supranuclear Palsy - Pipeline by Alterity Therapeutics Ltd, H1 2020
Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, H1 2020
Progressive Supranuclear Palsy - Pipeline by Aprinoia Therapeutics Inc, H1 2020
Progressive Supranuclear Palsy - Pipeline by Arvinas Inc, H1 2020
Progressive Supranuclear Palsy - Pipeline by Asceneuron SA, H1 2020
Progressive Supranuclear Palsy - Pipeline by AZTherapies Inc, H1 2020
Progressive Supranuclear Palsy - Pipeline by Cerebrum Therapeutics Inc, H1 2020
Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences Inc, H1 2020
Progressive Supranuclear Palsy - Pipeline by Declion Pharmaceuticals Inc, H1 2020
Progressive Supranuclear Palsy - Pipeline by EmeraMed Ltd, H1 2020
Progressive Supranuclear Palsy - Pipeline by Merck & Co Inc, H1 2020
Progressive Supranuclear Palsy - Dormant Projects, H1 2020
Progressive Supranuclear Palsy - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Progressive Supranuclear Palsy, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

AbbVie Inc

Alterity Therapeutics Ltd

AlzProtect SAS

Aprinoia Therapeutics Inc

Arvinas Inc

Asceneuron SA

AZTherapies Inc

Cerebrum Therapeutics Inc

Cortice Biosciences Inc

Declion Pharmaceuticals Inc

EmeraMed Ltd

Merck & Co Inc

NeuroTau Inc

New Amsterdam Sciences Inc

Pinteon Therapeutics Inc

Prothena Corp Plc

Retrotope Inc

TauC3 Biologics Ltd

TauRx Therapeutics Ltd

UCB SA

Voyager Therapeutics Inc

I would like to order

Product name: Progressive Supranuclear Palsy - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/P8D0E56EDD4EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P8D0E56EDD4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970